Shun Wen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

10 marzo 2021 09:05 Fonte: Adnkronos #chimica-e-farmacia TAICHUNG, March 10, 2021 /PRNewswire/ Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from the single-ascending-dose study of ALA-1000. A 3-month buprenorphine released injectable designed to be dosed subcutaneously for treating opioid use disorder (OUD). The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain severity. Opioid dependency: A world health issue The world-wide opioid epidemic is a documented public health crisis. Treatments for opioid abuse currently rely on Buprenorphine, Methadone, and Naltrexone as Medication-assisted treatment (MAT). However, patients n

Charles linPrnewswire alar pharmaceuticals incDalar pharmaceuticalsAlar pharmaceuticals incShun wenAlar pharmaceuticals establishedசார்லஸ் லின்அலார் மருந்துகள்அலார் மருந்துகள் இன்க்விலக்கு வென்அலார் மருந்துகள் நிறுவப்பட்டது